Compare GSK plc (GSK) vs NetEase Inc (NTES) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

NetEase (NTES) trades at $129.86, up 1.14% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $112.63 billion and net income of $33.76 billion, yielding a 29.84% margin. Recent Q1 2026 EPS beat expectations at $2.53 versus $2.19, though prior quarters missed. Cash flow from operations remains healthy at $50.74 billion in 2025, while the balance sheet holds $137.58 billion in cash against manageable debt.

Outlook is positive due to solid profitability, international expansion in gaming, and a 34.66% upside per analyst targets. Risks include China regulatory exposure and competitive pressures. The stock presents a value opportunity with a P/E of 16.5 below industry peers, supported by 81.82% buy ratings from analysts.